Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Conditions
Interventions
DR-01
Locations
37
United States
Dren Investigational Site
Birmingham, Alabama, United States
Dren Investigational Site
Duarte, California, United States
Dren Investigational Site
Irvine, California, United States
Dren Investigational Site
Redwood City, California, United States
Dren Investigational Site
New Haven, Connecticut, United States
Dren Investigational Site
Tampa, Florida, United States
Start Date
July 13, 2022
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
April 17, 2026
Lead Sponsor
Dren Bio
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions